Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER
申请人:Incyte Corporation
公开号:EP3510032A1
公开(公告)日:2019-07-17
[EN] PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE PYRAZOLOPYRIDINE COMME MODULATEURS DE HPK1 ET LEURS UTILISATIONS POUR LE TRAITEMENT DU CANCER
申请人:INCYTE CORP
公开号:WO2018049200A1
公开(公告)日:2018-03-15
Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.
PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF
申请人:Incyte Corporation
公开号:US20180072720A1
公开(公告)日:2018-03-15
Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.